A 48-year-old woman with chronic hypertension (BP 160/100 mmHg) is found on routine screening to have Grade II hypertensive retinopathy with arteriolar narrowing and AV nicking, but no hemorrhages or exudates. Which is the drug of choice for long-term management to prevent progression to sight-threatening retinopathy?

Explanation

## Chronic Hypertensive Retinopathy Prevention ### Clinical Context The patient has **Grade II hypertensive retinopathy** (arteriolar narrowing, AV nicking—early microvascular changes without hemorrhages or exudates). This requires **long-term BP control** to prevent progression to Grade III–IV (hemorrhages, exudates, papilledema) and vision loss. ### Why ACE Inhibitors (Lisinopril) Are First-Line **Key Point:** ACE inhibitors are the preferred class for chronic hypertensive retinopathy because they: 1. **Reduce intraglomerular pressure** — decrease efferent arteriolar vasoconstriction, protecting microvascular beds including retina 2. **Prevent microvascular remodeling** — inhibit angiotensin II–mediated hypertrophy and fibrosis of retinal arterioles 3. **Have renal protective effects** — prevent diabetic and hypertensive nephropathy (often coexist with retinopathy) 4. **Reduce proteinuria** — marker of microvascular disease regression 5. **Evidence-based** — multiple RCTs (MICRO-HOPE, ADVANCE) show ACEi/ARB reduce retinopathy progression ### Mechanism: Why ACEi Protects the Retina **Clinical Pearl:** Hypertensive retinopathy results from chronic endothelial injury and microvascular remodeling. Angiotensin II drives this via AT1 receptor activation, causing: - Arteriolar smooth muscle hypertrophy - Increased vascular permeability (exudates) - Endothelial dysfunction and microthrombi (hemorrhages) ACE inhibitors block this cascade at the source, preventing both acute vascular injury and chronic remodeling. ### Comparison of Antihypertensive Classes for Retinopathy | Class | Mechanism | Retinal Protection | Microvascular Remodeling | Evidence | |-------|-----------|-------------------|--------------------------|----------| | **ACE Inhibitor** | ↓ Ang II, ↓ efferent vasoconstriction | Excellent | Prevents hypertrophy | Strong (MICRO-HOPE, ADVANCE) | | **ARB** | ↓ Ang II (AT1 blockade) | Excellent | Prevents hypertrophy | Strong (equivalent to ACEi) | | Calcium channel blocker | Vasodilation, ↓ peripheral resistance | Moderate | Limited | Moderate | | Thiazide diuretic | ↓ Plasma volume, ↓ Na reabsorption | Weak | No | Weak | | Beta-blocker | ↓ HR, ↓ cardiac output | Weak | No | Weak | **High-Yield:** ARBs (losartan, valsartan) are **equally effective** to ACEi for retinopathy prevention and are preferred if ACEi causes cough. Both are superior to other classes for microvascular protection. ### Treatment Algorithm for Chronic Hypertensive Retinopathy ```mermaid flowchart TD A[Grade II Hypertensive Retinopathy<br/>BP 160/100 mmHg]:::outcome --> B{Target BP?}:::decision B -->|<140/90| C[ACE Inhibitor or ARB]:::action C --> D[Reduces Ang II<br/>Prevents arteriolar remodeling]:::outcome D --> E[Slows progression<br/>to Grade III-IV]:::outcome F[If ACEi intolerant<br/>cough] -->|Switch to| G[ARB]:::action H[Inadequate control] -->|Add| I[Calcium channel blocker<br/>or Thiazide]:::action ``` **Key Point:** Target BP in hypertensive retinopathy is **<140/90 mmHg** (or <130/80 if diabetic). Tight control with ACEi/ARB reduces retinopathy progression by ~30–50%. ### Why Other Classes Are Suboptimal **Warning:** Calcium channel blockers (amlodipine) cause peripheral vasodilation but do NOT address the underlying angiotensin-driven microvascular remodeling. They are second-line agents for add-on therapy, not monotherapy for retinopathy prevention. Thiazides and beta-blockers have minimal retinal protective effects and are not preferred for this indication, though they may be used in combination with ACEi/ARB. [cite:Harrison 21e Ch 297; Kanski Ophthalmology 8e Ch 13]